SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
2020; Nature Portfolio; Volume: 588; Issue: 7839 Linguagem: Inglês
10.1038/s41586-020-2852-1
ISSN1476-4687
AutoresChristopher O. Barnes, Claudia A. Jette, Morgan E. Abernathy, Kim-Marie A. Dam, Shannon R. Esswein, Harry B. Gristick, Andrey Malyutin, Naima G. Sharaf, Kathryn E. Huey‐Tubman, Yu E. Lee, Davide F. Robbiani, Michel C. Nussenzweig, Anthony P. West, Pamela J. Björkman,
Tópico(s)Viral gastroenteritis research and epidemiology
ResumoThe coronavirus disease 2019 (COVID-19) pandemic presents an urgent health crisis. Human neutralizing antibodies that target the host ACE2 receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein
Referência(s)